AstraZeneca vs General Motors: Founders, CEOs and History

Company facts

Founders

CEOs and their tenures

Timeline: AstraZeneca and General Motors side by side

1. 1908General Motors

   General Motors Founded

   William C. Durant incorporates General Motors in Hudson, New Jersey, on September 16, 1908, with Buick Motor Company as its primary asset.

2. 1909General Motors

   Cadillac and Oldsmobile Acquired

   GM acquires Oldsmobile and the prestigious Cadillac Automobile Company, establishing the multi-brand architecture that will define GM's market segmentation strategy for decades.

3. 1913AstraZeneca

   Astra AB Founded in Södertälje, Sweden

   400 doctors and apothecaries establish Astra AB to manufacture pharmaceuticals for the Swedish market, creating the foundation for what would become one of Europe's largest drug companies.

4. 1923General Motors

   Alfred Sloan Becomes President

   Alfred P. Sloan takes the GM presidency and begins implementing the decentralized divisional management structure and market segmentation strategy that transforms GM into the world's most admired corporate organization.

5. 1931General Motors

   GM Surpasses Ford as World's Largest Automaker

   General Motors overtakes Ford Motor Company as the world's largest automobile manufacturer by sales volume, a position it would hold for the majority of the next seven decades.

6. 1984General Motors

   Saturn Corporation Founded

   GM establishes Saturn as a separate subsidiary intended to compete with Japanese small cars through innovative labor relations, retail practices, and manufacturing processes.

7. 1993AstraZeneca

   Zeneca Group Spun Off from ICI

   Imperial Chemical Industries demerges its pharmaceuticals and agrochemicals businesses to form Zeneca Group PLC, with initial products including Zestril, Nolvadex, and Zoladex generating approximately $3.2 billion in annual sales.

8. 1996General Motors

   OnStar Connected Vehicle Service Launched

   GM introduces OnStar, the world's first embedded cellular connected vehicle service, offering emergency assistance, stolen vehicle tracking, and remote diagnostics.

9. 1999AstraZeneca

   Astra and Zeneca Merge to Form AstraZeneca

   The all-share merger of equals completes on 6 April 1999, creating AstraZeneca PLC.

10. 2000AstraZeneca

    Nexium Launch Replaces Prilosec

    AstraZeneca launches Nexium (esomeprazole), the single-isomer successor to Losec/Prilosec, in Europe in 2000 and in the United States in 2001 after FDA approval on 20 February 2001.

11. 2006AstraZeneca

    Acquisition of Cambridge Antibody Technology

    AstraZeneca agrees in May 2006 to buy Cambridge Antibody Technology for 1,320 pence a share, valuing the UK biotech at 702 million pounds or about $1.32 billion.

12. 2007AstraZeneca

    Acquisition of MedImmune for $15.6 Billion

    AstraZeneca acquires MedImmune for $15.6 billion, entering the biologics market and gaining the Synagis respiratory syncytial virus franchise and antibody technology platforms. The Gaithersburg facility becomes one of three global R&D centres.

13. 2009General Motors

    Chapter 11 Bankruptcy and Government Bailout

    General Motors files for Chapter 11 bankruptcy protection on June 1, 2009, with $49.5 billion in U.S. Government assistance as part of the Troubled Asset Relief Program.

14. 2010General Motors

    IPO Return to Public Markets

    General Motors returns to public markets through an initial public offering on November 18, 2010, raising approximately $23.1 billion - at the time one of the largest IPOs in U.S. History. The offering allows the U.S.

15. 2012AstraZeneca

    Pascal Soriot Appointed CEO

    Pascal Soriot joins AstraZeneca as Chief Executive Officer on October 1, 2012, with a base salary of $1.4 million and a mandate to reverse declining revenue and R&D productivity through science-led investment.

16. 2014AstraZeneca

    Pfizer Hostile Takeover Rejected

    AstraZeneca's board rejects a $117 billion hostile takeover offer from Pfizer, with Soriot arguing that the undervaluation would destroy long-term shareholder value and pipeline potential.

17. 2014AstraZeneca

    Acquisition of Almirall Respiratory Portfolio

    AstraZeneca acquires the respiratory portfolio of Spanish pharmaceutical company Almirall for approximately $2.1 billion, strengthening the company's position in COPD and asthma with products including Eklira and pipeline candidates that become Breztri.

18. 2014General Motors

    Mary Barra Becomes CEO

    Mary Barra, a 33-year GM veteran with a background in engineering and manufacturing, becomes CEO on January 15, 2014, becoming the first female CEO of a major global automaker.

19. 2015AstraZeneca

    Tagrisso Approved for EGFR-Mutated Lung Cancer

    The FDA approves Tagrisso (osimertinib) in November 2015 for metastatic EGFR T790M mutation-positive non-small cell lung cancer, the first product from Soriot's reinvestment strategy to reach market.

20. 2016General Motors

    Cruise Automation Acquired

    GM acquires Cruise Automation, a San Francisco-based autonomous vehicle startup, for approximately $1 billion - at the time one of the largest acquisitions in GM's modern history.

21. 2017AstraZeneca

    Imfinzi Approved Based on PACIFIC Trial

    The FDA approves Imfinzi (durvalumab) for unresectable stage III non-small cell lung cancer after chemoradiation, based on PACIFIC trial data showing survival benefits.

22. 2020AstraZeneca

    COVID-19 Vaccine Development with Oxford University

    AstraZeneca partners with the University of Oxford to develop and manufacture the Vaxzevria COVID-19 vaccine, distributing billions of doses globally at nonprofit pricing during the pandemic peak.

23. 2021AstraZeneca

    Acquisition of Alexion Pharmaceuticals for $39 Billion

    AstraZeneca completes the $39 billion acquisition of Alexion on July 21, 2021, entering the rare disease market with Soliris and Ultomiris and creating a dedicated rare disease unit headquartered in Boston.

24. 2021General Motors

    Ultium Platform and EV Commitment Announced

    GM announces its commitment to invest more than $35 billion in electric and autonomous vehicles through 2025 and introduces the Ultium battery platform as the technological foundation for dozens of future EV models across all four U.S. Brands.

25. 2023AstraZeneca

    CinCor Pharma Acquired for up to $1.8 Billion

    AstraZeneca agrees on 9 January 2023 to acquire CinCor Pharma for up to $1.8 billion, $26 per share in cash plus a $10 per share contingent value right, to gain baxdrostat, an aldosterone synthase inhibitor for resistant hypertension.

26. 2024AstraZeneca

    Total Revenue Reaches $54.073 Billion

    AstraZeneca reports Total Revenue of $54.073 billion for fiscal year 2024, an 18% increase at actual rates and 21% at constant exchange rates, with 16 blockbuster medicines, 74 regulatory events, and 24 pipeline progression events.

27. 2024AstraZeneca

    Fusion Pharmaceuticals and Gracell Acquisitions

    AstraZeneca acquires Fusion Pharmaceuticals for $2 billion to access radiopharmaceutical technology and Gracell Biotechnologies for $1.2 billion for cell therapy manufacturing, expanding modality diversity into radiopharmaceuticals and CAR-T.

28. 2024General Motors

    Cruise Robotaxi Program Ended

    Following the October 2023 Cruise pedestrian incident and a long operational pause, GM announced in December 2024 that it would stop funding Cruise's robotaxi business and fold the unit's technology work into GM.

29. 2025AstraZeneca

    Total Revenue Reaches $58.739 Billion

    AstraZeneca reports Total Revenue of $58.739 billion for fiscal year 2025, an 8% increase at constant exchange rates, with 16 positive Phase III readouts, 43 major market approvals, and a commitment to invest $50 billion in U.S. manufacturing by 2030.

30. 2025AstraZeneca

    EsoBiotec Acquired for Up to $1 Billion

    AstraZeneca acquires Belgian biotech EsoBiotec for up to $1 billion to access in vivo cell therapy technology, eliminating the need for ex vivo manufacturing in CAR-T therapies.

31. 2025AstraZeneca

    $50 Billion US Manufacturing and R&D Commitment

    AstraZeneca announces on 21 July 2025 that it will invest $50 billion in United States manufacturing and research by 2030, including a new Virginia facility later raised to $4.5 billion.

32. 2025General Motors

    EV Capacity Cut and $7.6 Billion in EV Charges

    After the U.S. federal EV tax credit expired on September 30, 2025, GM cut EV production capacity and recorded about $7.6 billion of EV-related charges for the year.

33. 2026AstraZeneca

    Ordinary Shares Begin Trading on the NYSE

    AstraZeneca ordinary shares start trading on the New York Stock Exchange on 2 February 2026 under the ticker AZN, after the American Depositary Share programme and certain debt securities stopped trading on Nasdaq on 30 January 2026.

34. 2026AstraZeneca

    Baxfendy Approved in the US for Hypertension

    The FDA approves Baxfendy (baxdrostat) in May 2026 as the first aldosterone synthase inhibitor for hypertension, used in combination with other antihypertensives in adults who are not adequately controlled.

35. 2026AstraZeneca

    $15 Billion China Investment Through 2030

    AstraZeneca announces on 29 January 2026 that it will invest $15 billion in China through 2030 to expand manufacturing and research, in a market that is its second largest and about 12% of revenue.

36. 2026General Motors

    Guidance Raised as North America Margins Recover

    GM reported Q2 2026 revenue of $48.0 billion and EBIT-adjusted of $3.9 billion, with North America margins back in its 8-10% target range, and raised full-year 2026 EBIT-adjusted guidance to $14.0-16.0 billion.

Acquisitions

Questions about AstraZeneca vs General Motors